Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Tools & Technology » Informatics » CombiChem Achieves Milestones, Holds IPO

CombiChem Achieves Milestones, Holds IPO

Dec 18, 1998
Premium

SAN DIEGO, Calif.--After its initial public offering earlier this month, CombiChem announced the achievement of milestones in two of its collaborations. The computational chemistry company here offered 2.25 million shares at $8 per share in the offering managed by BancAmerica Robertson Stephens, Donaldson, Lufkin & Jenrette, and Salomon Smith Barney. CombiChem offered underwriters an option to buy an additional 337,500 shares of common stock to cover over-allotments.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Scan

This Time, Novavax

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Shortened Visas for Some Students

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

New York's Own Review

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

Science Papers Examine Y Chromosomes of Archaic Humans, Schistosomiasis Therapeutic Targets

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.

Sep
30
Featured Webinar

Moving from Non-Invasive Prenatal Screening to Prenatal Diagnostics: An Expert Panel Discussion

Sponsored by
LGC SeraCare Life Sciences

Non-invasive prenatal testing (NIPT) continues to expand globally to support maternal-fetal patient care. 

Oct
01
Featured Webinar

Immune Repertoire Sequencing to Uncover SARS-CoV-2-Specific T Cell Responses and Dynamics

Sponsored by
Adaptive Biotechnologies

T cells are the adaptive immune system’s first responders to any virus, circulating in the blood to detect and quickly multiply to attack the virus, and also support the development of antibodies by B cells. 

Oct
08
Featured Webinar

Novel Applications of RNA-based Precision Oncology: From Drug Tolerability to Immunogenomics

Sponsored by
Genecentric

This webinar, Part 3 of the “Advances in RNA-based Biomarker Development for Precision Oncology” webinar series sponsored by GeneCentric Therapeutics, will discuss novel and emerging applications of RNA-based genomic analysis in precision oncology, form characterizing the tumor microenvironment to informing the development of immuno-oncology treatments.

Oct
21
Featured Webinar

Target Enrichment NGS Panel Outperforms the Gold Standard for Sequence and CNV Analysis

Sponsored by
Roche

Target enrichment has been a major driver behind the clinical adoption of next-generation sequencing (NGS) over the last decade because it simplifies analysis and provides a cost-effective method of massive parallel resequencing. It has not only replaced Sanger sequencing, but it is actively dispensing the need for parallel copy number variant (CNV) analysis using classic techniques.

What's Popular?

In Informatics

  1. Clear Labs Nanopore Sequencing Coronavirus Test Gets FDA Emergency Use Authorization

  2. Catalog DNA Merges Molecular Biology, Information Theory to Pursue DNA-Based Computing

    Premium

  3. Google DeepVariant Boosts Accuracy of Indel Calls in PacBio Long Reads

    Premium

  4. M2Gen Expands Partnership With Discovery Life Sciences

  5. Center for Genomic Regulation's COVID-19 Viral Beacon Digs Into Thousands of SARS-CoV-2 Genomes

    Premium

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.